Real-World Precision Medicine: Proteogenomics to Accelerate Drug Development and Patient Care

Chair: Henry Rodriguez, USA

Co-chair: Yu-Ju Chen, Taiwan

Speaker: Matthew Ellis, USA - New Prospects for Killing ER+ Breast Cancer (Micro-scale Proteogenomics)

Speaker: Amanda Paulovich, USA - Building New Clinical Solutions for Precision Oncology via Proteogenomics

Speaker: Albert Sickmann, Germany - Proteogenomics/Proteomics: Complementing Precision Medicine with Phenotypic Data

Ever since the announcement of the Precision Medicine Initiative, there have been increasing efforts to identify and understand the basis of cancer using high-throughput technologies and the development of specialized treatments for specific subtypes of cancer, based on molecular evidence. Clinical proteogenomics is an exciting opportunity to complement the gene testing-centric clinical community for precision medicine. However, translating proteomic measurements to real-world patient care requires synergy of multiple requirements: meaningful and actionable molecular characterization, clinical and analytical validation, defining diagnosis values, and meeting regulatory compliance.

This HUPO session showcases clinical researchers discussing their stories and strategies to move proteomics towards better patient/clinical care. During this interactive broadcast, learn about the insight of three stories:

  • Microscaled proteogenomics technology for predicting response of triple negative breast cancer
  • Development of robust targeted platforms for clinical laboratory tests, drug development, and clinical trials
  • Proteogenomics/Proteomics: Complementing Precision Medicine with Phenotypic Data
Henry Rodriguez

Dr. Henry Rodriguez is the Founding Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Rodriguez is also a member of NCI’s Senior Leadership. A cell and molecular biologist with a background in business, Dr. Rodriguez’s biomedical research has focused on mechanisms of cancer in basic and clinical science, and the development of measurement science, standards, and technology.

Dr. Rodriguez earned his A.A. in biology from Miami Dade College, B.S. in biology/chemistry and M.S. in biology from Florida International University, Ph.D. in cell and molecular biology from Boston University, and M.B.A. in finance and management from Johns Hopkins University Carey Business School. Fellowships were conducted at the Scripps Research Institute and City of Hope Comprehensive Cancer Center. Dr. Rodriguez has authored more than 147 original research papers, including co-editing a book on oxidative stress and aging.


Yu-Ju Chen

Yu-Ju Chen received Ph.D. degree in physical chemistry from Iowa State University. After postdoctoral work at Ames Laboratory, USA and National Tsing Hua University, Dr. Chen joined the Institute of Chemistry of Academia Sinica and is currently a Distinguished Research Fellow. She is also the President of Human Proteome Organization, past Vice President of Asia Oceana Human Proteome Organization, past President of Taiwan Proteomics Society and Taiwan Society for Mass Spectrometry. Dr. Chen is the Associate Editor of Analytical Chemistry and editorial board member of the Proteomics and Scientific Report.

Towards comprehensive profiling of human proteome, Dr. Chen’s interests focus on integrating nanomaterials, advanced mass spectrometry and bioinformatics to develop advanced proteomics technologies for quantitative membrane proteomics and protein post-translational modification. She also established extensive domestic and international collaboration network to apply proteomic methodologies to delineate the disease mechanism in cancer biology.

Matthew Ellis MB., BChir., Ph.D., FRCP
As Director for the Lester and Sue Smith Breast Center at Baylor College of Medicine I coordinate an interdisciplinary team of oncologists, pathologists, epidemiologists, basic scientists and statisticians focused on improving the prevention, detection and treatment of breast cancer.  I bring to this position considerable experience in the oversight and execution of large projects and clinical trials of a collaborative nature on a nationwide basis. I have a strong background in molecular cell biology, molecular pharmacology, genomics and proteomics. I have been an active member of the National Clinical Trials network for over 20 years, and I am a Vice Chair for the NRG Breast Committee.  I an Co-leader for The Cancer Genome Atlas (TCGA) Breast Project where I established collaborations with several Genome Centers on massive parallel sequencing of breast cancer (Nature 2010, 2012).  I am a PI in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) which is focused on translating proteogenomic findings into improvements in the diagnosis and treatment of breast and other cancers (Nature 2016, Nature Communications 2020, Cell 2020). I am also the principal investigator for the Baylor College of Medicine Breast Cancer SPORE, awarded in 2020.  Our SPORE focuses on new treatment approaches for advanced breast cancer.
Amanda Paulovich MD, PhD
Dr. Paulovich completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Oncology at Dana-Farber Cancer Institute.  She completed her PhD. training in genetics with Dr. Lee Hartwell at University of Washington and postdoctoral training in genomics at the Massachusetts Institute of Technology with Dr. Eric Lander.  As an oncologist, Dr. Paulovich was struck by the paucity of quantitative assays for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice “personalized medicine.” Out of these experiences, she became passionate about developing technologies and strategies for translation of novel diagnostics and therapeutics to enable precision medicine.  Over the past 18 years, Dr. Paulovich's interdisciplinary laboratory has focused on proteogenomic approaches to understanding cancer biology and laying the groundwork for the clinical translation of novel diagnostics based on targeted, multiple reaction monitoring (MRM) mass spectrometry.
Albert Sickmann PhD
Albert Sickmann studied biochemistry and did his PhD in chemistry (2001). After his PostDoc he became group leader at the DFG funded Rudolf-Virchow Center for Experimental Biomedicine (2003), Associate Professor for Protein Mass spectrometry (2007, University of Würzburg) and Full Professor for Bioanalytics and applied Proteomics (2008, University of Bochum). Since 2008 he is Director at the Leibniz-Institute for Analytical Sciences (ISAS). He served as president of the german proteomics society (DGPF, 2013-2017) and was member of the board of the European Proteomics Association (EuPA, 2015-2020). Since 2016 he is member of the International Cancer Proteogenome Consortium (ICPC). His research focus on the molecular understanding of platelet function in health (genetic variation, life span) and disease (cardiovascular disease, cancer) using mass spectrometry based methods and their application for clinical samples.

To view this presentation, please login with your HUPO Connect Webinar Series login credentials. If you do not have an account or access to this presentation, please click here to register an account.